Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status
Martin Nilsson(Lund University), Niklas Loman(Lund University), Oskar T. Johannsson(Lapland Central Hospital), Ingrid Idvall(Lund University), Ulf Kristoffersson, Linda Hartman(Lund University)
Cited by 29
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
|Cancer Cell|2017|534